OP0308 Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2a, randomised, double-blind, placebo-controlled study

Abstract

ObjectivesEvaluate efficacy and safety of guselkumab (GUS) in patients (pts) with active psoriatic arthritis (PsA) over 56 weeks (wks).MethodsPts w/active PsA (defined as ≥3 tender and ≥3 swollen joints, C-reactive...